Cargando…
Down-Regulation of CD9 by Methylation Decreased Bortezomib Sensitivity in Multiple Myeloma
Bortezomib therapy has been proven successful for the treatment of relapsed and/or refractory multiple myeloma (MM). However, both intrinsic and acquired resistance has already been observed. In this study, we explored the relationship between CD9 expression and bortezomib sensitivity in MM. We foun...
Autores principales: | Hu, Xiaotong, Xuan, Han, Du, Huaping, Jiang, Hao, Huang, Jinwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008425/ https://www.ncbi.nlm.nih.gov/pubmed/24788635 http://dx.doi.org/10.1371/journal.pone.0095765 |
Ejemplares similares
-
PB2079: LACTATE DECREASES BORTEZOMIB SENSITIVITY AND PREDICTS POOR CLINICAL OUTCOMES OF MULTIPLE MYELOMA
por: MA, Naya, et al.
Publicado: (2023) -
ClC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy
por: Zhang, Huimin, et al.
Publicado: (2018) -
Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009) -
Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib
por: Zhao, Yinghao, et al.
Publicado: (2015) -
β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib
por: Wu, Cuicui
Publicado: (2022)